McKenna, K., A.S. Beignon, and N. Bhardwaj, Plasmacytoid dendritic cells: linking innate and adaptive immunity. J Virol, 2005. 79(1): p. 17–27.
Shortman, K. and Y.J. Liu, Mouse and human dendritic cell subtypes. Nat Rev Immunol, 2002. 2(3): p. 151–61.
Ebner, S., et al., Expression of C-type lectin receptors by subsets of dendritic cells in human skin. Int Immunol, 2004. 16(6): p. 877–87.
Rafiq, K., A. Bergtold, and R. Clynes, Immune complex-mediated antigen presentation induces tumor immunity. J Clin Invest, 2002. 110(1): p. 71–9.
Albert, M.L., et al., Immature dendritic cells phagocytose apoptotic cells via alphavbeta5 and CD36, and cross-present antigens to cytotoxic T lymphocytes. J Exp Med, 1998. 188(7): p. 1359–68.
Bonifaz, L., et al., Efficient targeting of protein antigen to the dendritic cell receptor DEC-205 in the steady state leads to antigen presentation on major histocompatibility complex class I products and peripheral CD8+ T cell tolerance. J Exp Med, 2002. 196(12): p. 1627–38.
Peiser, L., S. Mukhopadhyay, and S. Gordon, Scavenger receptors in innate immunity. Curr Opin Immunol, 2002. 14(1): p. 123–8.
Basu, S., et al., CD91 is a common receptor for heat shock proteins gp96, hsp90, hsp70, and calreticulin. Immunity, 2001. 14(3): p. 303–13.
Delneste, Y., et al., Involvement of LOX-1 in dendritic cell-mediated antigen cross-presentation. Immunity, 2002. 17(3): p. 353–62.
Guermonprez, P., et al., Antigen presentation and T cell stimulation by dendritic cells. Annu Rev Immunol, 2002. 20: p. 621–67.
Chow, A., et al., Dendritic cell maturation triggers retrograde MHC class II transport from lysosomes to the plasma membrane. Nature, 2002. 418(6901): p. 988–94.
Guermonprez, P., et al., ER-phagosome fusion defines an MHC class I cross-presentation compartment in dendritic cells. Nature, 2003. 425(6956): p. 397–402.
Fonteneau, J.F., M. Larsson, and N. Bhardwaj, Interactions between dead cells and dendritic cells in the induction of antiviral CTL responses. Curr Opin Immunol, 2002. 14(4): p. 471–7.
Ackerman, A.L., et al., Early phagosomes in dendritic cells form a cellular compartment sufficient for cross presentation of exogenous antigens. Proc Natl Acad Sci U S A, 2003. 100(22): p. 12889–94.
Houde, M., et al., Phagosomes are competent organelles for antigen cross-presentation. Nature, 2003. 425(6956): p. 402–6.
Lizee, G., et al., Control of dendritic cell cross-presentation by the major histocompatibility complex class I cytoplasmic domain. Nat Immunol, 2003. 4(11): p. 1065–73.
Wolkers, M.C., et al., Antigen bias in T cell cross-priming. Science, 2004. 304(5675): p. 1314–7.
Moody, D.B. and S.A. Porcelli, Intracellular pathways of CD1 antigen presentation. Nat Rev Immunol, 2003. 3(1): p. 11–22.
Joyce, S. and L. Van Kaer, CD1-restricted antigen presentation: an oily matter. Curr Opin Immunol, 2003. 15(1): p. 95–104.
Fujii, S., et al., Prolonged IFN-gamma-producing NKT response induced with alpha-galactosylceramide-loaded DCs. Nat Immunol, 2002. 3(9): p. 867–74.
Fujimoto, Y., et al., CD83 expression influences CD4+ T cell development in the thymus. Cell, 2002. 108(6): p. 755–67.
Lechmann, M., et al., CD83 on dendritic cells: more than just a marker for maturation. Trends Immunol, 2002. 23(6): p. 273–5.
Matzinger, P., The danger model: a renewed sense of self. Science, 2002. 296(5566): p. 301–5.
Skoberne, M., A.S. Beignon, and N. Bhardwaj, Danger signals: a time and space continuum. Trends Mol Med, 2004. 10(6): p. 251–7.
Cheng, F., et al., A critical role for Stat3 signaling in immune tolerance. Immunity, 2003. 19(3): p. 425–36.
Kadowaki, N., et al., Subsets of human dendritic cell precursors express different toll-like receptors and respond to different microbial antigens. J Exp Med, 2001. 194(6): p. 863–9.
Hornung, V., et al., Quantitative expression of toll-like receptor 1–10 mRNA in cellular subsets of human peripheral blood mononuclear cells and sensitivity to CpG oligodeoxynucleotides. J Immunol, 2002. 168(9): p. 4531–7.
Jarrossay, D., et al., Specialization and complementarity in microbial molecule recognition by human myeloid and plasmacytoid dendritic cells. Eur J Immunol, 2001. 31(11): p. 3388–93.
Delamarre, L., et al., Differential lysosomal proteolysis in antigen-presenting cells determines antigen fate. Science, 2005. 307(5715): p. 1630–4.
Delamarre, L., H. Holcombe, and I. Mellman, Presentation of exogenous antigens on major histocompatibility complex (MHC) class I and MHC class II molecules is differentially regulated during dendritic cell maturation. J Exp Med, 2003. 198(1): p. 111–22.
Datta, S.K., et al., A subset of Toll-like receptor ligands induces cross-presentation by bone marrow-derived dendritic cells. J Immunol, 2003. 170(8): p. 4102–10.
Shin, T., et al., Cooperative B7–1/2 (CD80/CD86) and B7-DC costimulation of CD4+ T cells independent of the PD-1 receptor. J Exp Med, 2003. 198(1): p. 31–8.
Nguyen, L.T., et al., Cross-linking the B7 family molecule B7-DC directly activates immune functions of dendritic cells. J Exp Med, 2002. 196(10): p. 1393–8.
Suh, W.K., et al., The B7 family member B7-H3 preferentially down-regulates T helper type 1-mediated immune responses. Nat Immunol, 2003. 4(9): p. 899–906.
Zang, X., et al., B7x: a widely expressed B7 family member that inhibits T cell activation. Proc Natl Acad Sci U S A, 2003. 100(18): p. 10388–92.
Colonna, M., TREMs in the immune system and beyond. Nat Rev Immunol, 2003. 3(6): p. 445–53.
Kolb-Maurer, A., et al., Production of IL-12 and IL-18 in human dendritic cells upon infection by Listeria monocytogenes. FEMS Immunol Med Microbiol, 2003. 35(3): p. 255–62.
Dzionek, A., et al., BDCA-2, a novel plasmacytoid dendritic cell-specific type II C-type lectin, mediates antigen capture and is a potent inhibitor of interferon alpha/beta induction. J Exp Med, 2001. 194(12): p. 1823–34.
Randolph, G.J., G. Sanchez-Schmitz, and V. Angeli, Factors and signals that govern the migration of dendritic cells via lymphatics: recent advances. Springer Semin Immunopathol, 2004.
Ohl, L., et al., CCR7 governs skin dendritic cell migration under inflammatory and steady-state conditions. Immunity, 2004. 21(2): p. 279–88.
Steinman, R.M. and M.C. Nussenzweig, Avoiding horror autotoxicus: the importance of dendritic cells in peripheral T cell tolerance. Proc Natl Acad Sci U S A, 2002. 99(1): p. 351–8.
Dhodapkar, M.V., et al., Antigen-specific inhibition of effector T cell function in humans after injection of immature dendritic cells. J Exp Med, 2001. 193(2): p. 233–8.
Banchereau, J., et al., Immune and clinical responses in patients with metastatic melanoma to CD34(+) progenitor-derived dendritic cell vaccine. Cancer Res, 2001. 61(17): p. 6451–8.
Adams, S., D. O’Neill, and N. Bhardwaj, Maturation matters: importance of maturation for antitumor immunity of dendritic cell vaccines. J Clin Oncol, 2004. 22(18): p. 3834–5; author reply 3835.
Mossman, K.D., et al., Altered TCR signaling from geometrically repatterned immunological synapses. Science, 2005. 310(5751): p. 1191–3.
Stoll, S., et al., Dynamic imaging of T cell-dendritic cell interactions in lymph nodes. Science, 2002. 296(5574): p. 1873–6.
Bousso, P. and E. Robey, Dynamics of CD8+ T cell priming by dendritic cells in intact lymph nodes. Nat Immunol, 2003. 4(6): p. 579–85.
Gett, A.V., et al., T cell fitness determined by signal strength. Nat Immunol, 2003. 4(4): p. 355–60.
van Stipdonk, M.J., et al., Dynamic programming of CD8+ T lymphocyte responses. Nat Immunol, 2003. 4(4): p. 361–5.
Tato, C.M., A. Laurence, and J.J. O’Shea, Helper T cell differentiation enters a new era: le roi est mort; vive le roi! J Exp Med, 2006. 203(4): p. 809–12.
Akbari, O., R.H. DeKruyff, and D.T. Umetsu, Pulmonary dendritic cells producing IL-10 mediate tolerance induced by respiratory exposure to antigen. Nat Immunol, 2001. 2(8): p. 725–31.
Mora, J.R., et al., Selective imprinting of gut-homing T cells by Peyer’s patch dendritic cells. Nature, 2003. 424(6944): p. 88–93.
Hoebe, K., et al., Identification of Lps2 as a key transducer of MyD88-independent TIR signalling. Nature, 2003. 424(6950): p. 743–8.
Weiner, H.L., The mucosal milieu creates tolerogenic dendritic cells and T(R)1 and T(H)3 regulatory cells. Nat Immunol, 2001. 2(8): p. 671–2.
Shedlock, D.J. and H. Shen, Requirement for CD4 T cell help in generating functional CD8 T cell memory. Science, 2003. 300(5617): p. 337–9.
Karsunky, H., et al., Flt3 ligand regulates dendritic cell development from Flt3+ lymphoid and myeloid-committed progenitors to Flt3+ dendritic cells in vivo. J Exp Med, 2003. 198(2): p. 305–13.
Schoenberger, S.P., et al., T-cell help for cytotoxic T lymphocytes is mediated by CD40-CD40L interactions. Nature, 1998. 393(6684): p. 480–3.
Croft, M., Co-stimulatory members of the TNFR family: keys to effective T-cell immunity? Nat Rev Immunol, 2003. 3(8): p. 609–20.
Rogers, P.R., et al., OX40 promotes Bcl-xL and Bcl-2 expression and is essential for long-term survival of CD4 T cells. Immunity, 2001. 15(3): p. 445–55.
Janssen, E.M., et al., CD4+ T-cell help controls CD8+ T-cell memory via TRAIL-mediated activation-induced cell death. Nature, 2005. 434(7029): p. 88–93.
Thurner, B., et al., Generation of large numbers of fully mature and stable dendritic cells from leukapheresis products for clinical application. J Immunol Methods, 1999. 223(1): p. 1–15.
O’Neill, D. and N. Bhardwaj, Generation of autologous peptide- and protein-pulsed dendritic cells for patient-specific immunotherapy. Methods Mol Med, 2005. 109: p. 97–112.
Hsu, F.J., et al., Vaccination of patients with B-cell lymphoma using autologous antigen- pulsed dendritic cells. Nat Med, 1996. 2(1): p. 52–8.
Kiertscher, S.M., et al., Granulocyte/macrophage-colony stimulating factor and interleukin-4 expand and activate type-1 dendritic cells (DC1) when administered in vivo to cancer patients. Int J Cancer, 2003. 107(2): p. 256–61.
Slingluff, C., et al., Clinical and Immunologic Results of a Randomized Phase II Trial of Vaccination Using Four Melanoma Peptides Either Administered in Granulocyte-Macrophage Colony-Stimulating Factor in Adjuvant or Pulsed on Dendritic Cells. J. Clin. Oncol., 2003(November): p. 4016–4026.
Jonuleit, H., et al., A comparison of two types of dendritic cell as adjuvants for the induction of melanoma-specific T-cell responses in humans following intranodal injection. Int J Cancer, 2001. 93(2): p. 243–51.
Jonuleit, H., et al., Pro-inflammatory cytokines and prostaglandins induce maturation of potent immunostimulatory dendritic cells under fetal calf serum-free conditions. Eur J Immunol, 1997. 27(12): p. 3135–42.
Sato, E., et al., Intraepithelial CD8+ tumor-infiltrating lymphocytes and a high CD8+/regulatory T cell ratio are associated with favorable prognosis in ovarian cancer. Proc Natl Acad Sci U S A, 2005. 102(51): p. 18538–43.
Dave, S.S., et al., Prediction of survival in follicular lymphoma based on molecular features of tumor-infiltrating immune cells. N Engl J Med, 2004. 351(21): p. 2159–69.
Hanada, K., J.W. Yewdell, and J.C. Yang, Immune recognition of a human renal cancer antigen through post-translational protein splicing. Nature, 2004. 427(6971): p. 252–6.
Vigneron, N., et al., An antigenic peptide produced by peptide splicing in the proteasome. Science, 2004. 304(5670): p. 587–90.
Warren, E.H., et al., An antigen produced by splicing of noncontiguous peptides in the reverse order. Science, 2006. 313(5792): p. 1444–7.
Simpson, A.J., et al., Cancer/testis antigens, gametogenesis and cancer. Nat Rev Cancer, 2005. 5(8): p. 615–25.
Schuler-Thurner, B., et al., Rapid induction of tumor-specific type 1 T helper cells in metastatic melanoma patients by vaccination with mature, cryopreserved, peptide- loaded monocyte-derived dendritic cells. J Exp Med, 2002. 195(10): p. 1279–88.
Nestle, F.O., et al., Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells. Nat Med, 1998. 4(3): p. 328–32.
Dhodapkar, M.V., et al., Rapid generation of broad T-cell immunity in humans after a single injection of mature dendritic cells. J Clin Invest, 1999. 104(2): p. 173–80.
Fong, L., et al., Altered peptide ligand vaccination with Flt3 ligand expanded dendritic cells for tumor immunotherapy. Proc Natl Acad Sci U S A, 2001. 98(15): p. 8809–14.
Wang, R.F. and H.Y. Wang, Enhancement of antitumor immunity by prolonging antigen presentation on dendritic cells. Nat Biotechnol, 2002. 20(2): p. 149–54.
Berzofsky, J.A., J.D. Ahlers, and I.M. Belyakov, Strategies for designing and optimizing new generation vaccines. Nat Rev Immunol, 2001. 1(3): p. 209–19.
Timmerman, J.M., et al., Idiotype-pulsed dendritic cell vaccination for B-cell lymphoma: clinical and immune responses in 35 patients. Blood, 2002. 99(5): p. 1517–26.
Heiser, A., et al., Autologous dendritic cells transfected with prostate-specific antigen RNA stimulate CTL responses against metastatic prostate tumors. J Clin Invest, 2002. 109(3): p. 409–17.
Engelmayer, J., et al., Mature dendritic cells infected with canarypox virus elicit strong anti- human immunodeficiency virus CD8+ and CD4+ T-cell responses from chronically infected individuals. J Virol, 2001. 75(5): p. 2142–53.
Dietz, A.B. and S. Vuk-Pavlovic, High efficiency adenovirus-mediated gene transfer to human dendritic cells. Blood, 1998. 91(2): p. 392–8.
Su, Z., et al., Immunological and clinical responses in metastatic renal cancer patients vaccinated with tumor RNA-transfected dendritic cells. Cancer Res, 2003. 63(9): p. 2127–33.
Thumann, P., et al., Antigen loading of dendritic cells with whole tumor cell preparations. J Immunol Methods, 2003. 277(1–2): p. 1–16.
Parkhurst, M.R., et al., Hybrids of dendritic cells and tumor cells generated by electrofusion simultaneously present immunodominant epitopes from multiple human tumor-associated antigens in the context of MHC class I and class II molecules. J Immunol, 2003. 170(10): p. 5317–25.
Morse, M.A., et al., Migration of human dendritic cells after injection in patients with metastatic malignancies. Cancer Res, 1999. 59(1): p. 56–8.
Mackensen, A., et al., Homing of intravenously and intralymphatically injected human dendritic cells generated in vitro from CD34+ hematopoietic progenitor cells. Cancer Immunol Immunother, 1999. 48(2–3): p. 118–22.
Mullins, D.W., et al., Route of Immunization with Peptide-pulsed Dendritic Cells Controls the Distribution of Memory and Effector T Cells in Lymphoid Tissues and Determines the Pattern of Regional Tumor Control. J Exp Med, 2003. 198(7): p. 1023–34.
Fong, L., et al., Dendritic cells injected via different routes induce immunity in cancer patients. J Immunol, 2001. 166(6): p. 4254–9.
Ridolfi, R., et al., Evaluation of in vivo labelled dendritic cell migration in cancer patients. J Transl Med, 2004. 2(1): p. 27.
Nair, S., et al., Injection of immature dendritic cells into adjuvant-treated skin obviates the need for ex vivo maturation. J Immunol, 2003. 171(11): p. 6275–82.
Suzuki, H., et al., Imiquimod, a topical immune response modifier, induces migration of Langerhans cells. J Invest Dermatol, 2000. 114(1): p. 135–41.
Badovinac, V.P., et al., Accelerated CD8+ T-cell memory and prime-boost response after dendritic-cell vaccination. Nat Med, 2005. 11(7): p. 748–56.
Ridgway, D., The first 1000 dendritic cell vaccinees. Cancer Invest, 2003. 21(6): p. 873–86.
Therasse, P., et al., New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst, 2000. 92(3): p. 205–16.
Schadendorf, D., et al., Dacarbazine (DTIC) versus vaccination with autologous peptide-pulsed dendritic cells (DC) in first-line treatment of patients with metastatic melanoma: a randomized phase III trial of the DC study group of the DeCOG. Ann Oncol, 2006. 17(4): p. 563–70.
Holtl, L., et al., Immunotherapy of metastatic renal cell carcinoma with tumor lysate-pulsed autologous dendritic cells. Clin Cancer Res, 2002. 8(11): p. 3369–76.
O’Rourke, M.G., et al., Durable complete clinical responses in a phase I/II trial using an autologous melanoma cell/dendritic cell vaccine. Cancer Immunol Immunother, 2003. 52(6): p. 387–95.
Maier, T., et al., Vaccination of patients with cutaneous T-cell lymphoma using intranodal injection of autologous tumor-lysate-pulsed dendritic cells. Blood, 2003. 102(7): p. 2338–44.
Antonia, S.J., et al., Combination of p53 cancer vaccine with chemotherapy in patients with extensive stage small cell lung cancer. Clin Cancer Res, 2006. 12(3 Pt 1): p. 878–87.
Arnould, L., et al., Trastuzumab-based treatment of HER2-positive breast cancer: an antibody-dependent cellular cytotoxicity mechanism? Br J Cancer, 2006. 94(2): p. 259–67.
Babatz, J., et al., Induction of cellular immune responses against carcinoembryonic antigen in patients with metastatic tumors after vaccination with altered peptide ligand-loaded dendritic cells. Cancer Immunol Immunother, 2006. 55(3): p. 268–76.
Di Pucchio, T., et al., Immunization of stage IV melanoma patients with Melan-A/MART-1 and gp100 peptides plus IFN-alpha results in the activation of specific CD8(+) T cells and monocyte/dendritic cell precursors. Cancer Res, 2006. 66(9): p. 4943–51.
Fuessel, S., et al., Vaccination of hormone-refractory prostate cancer patients with peptide cocktail-loaded dendritic cells: results of a phase I clinical trial. Prostate, 2006. 66(8): p. 811–21.
Lou, E., et al., A phase II study of active immunotherapy with PANVAC or autologous, cultured dendritic cells infected with PANVAC after complete resection of hepatic metastases of colorectal carcinoma. Clin Colorectal Cancer, 2006. 5(5): p. 368–71.
Loveland, B.E., et al., Mannan-MUC1-pulsed dendritic cell immunotherapy: a phase I trial in patients with adenocarcinoma. Clin Cancer Res, 2006. 12(3 Pt 1): p. 869–77.
Perambakam, S., et al., Induction of specific T cell immunity in patients with prostate cancer by vaccination with PSA146–154 peptide. Cancer Immunol Immunother, 2006. 55(9): p. 1033–42.
Thomas-Kaskel, A.K., et al., Vaccination of advanced prostate cancer patients with PSCA and PSA peptide-loaded dendritic cells induces DTH responses that correlate with superior overall survival. Int J Cancer, 2006.
Trakatelli, M., et al., A new dendritic cell vaccine generated with interleukin-3 and interferon-beta induces CD8+ T cell responses against NA17-A2 tumor peptide in melanoma patients. Cancer Immunol Immunother, 2006. 55(4): p. 469–74.
Tuettenberg, A., et al., Induction of strong and persistent MelanA/MART-1-specific immune responses by adjuvant dendritic cell-based vaccination of stage II melanoma patients. Int J Cancer, 2006. 118(10): p. 2617–27.
Wierecky, J., M. Mueller, and P. Brossart, Dendritic cell-based cancer immunotherapy targeting MUC-1. Cancer Immunol Immunother, 2006. 55(1): p. 63–7.
Osada, T., et al., NK cell activation by dendritic cell vaccine: a mechanism of action for clinical activity. Cancer Immunol Immunother, 2006. 55(9): p. 1122–31.
Wilson, N.S., et al., Systemic activation of dendritic cells by Toll-like receptor ligands or malaria infection impairs cross-presentation and antiviral immunity. Nat Immunol, 2006. 7(2): p. 165–72.
Dillon, S., et al., Yeast zymosan, a stimulus for TLR2 and dectin-1, induces regulatory antigen-presenting cells and immunological tolerance. J Clin Invest, 2006. 116(4): p. 916–28.
Su, Z., et al., Enhanced induction of telomerase-specific CD4(+) T cells using dendritic cells transfected with RNA encoding a chimeric gene product. Cancer Res, 2002. 62(17): p. 5041–8.
Merad, M., et al., In vivo manipulation of dendritic cells to induce therapeutic immunity. Blood, 2002. 99(5): p. 1676–82.
Cho, H.J., et al., Immunostimulatory DNA-based vaccines induce cytotoxic lymphocyte activity by a T-helper cell-independent mechanism. Nat Biotechnol, 2000. 18(5): p. 509–14.
Schneeberger, A., et al., CpG motifs are efficient adjuvants for DNA cancer vaccines. J Invest Dermatol, 2004. 123(2): p. 371–9.
Weeratna, R.D., et al., TLR agonists as vaccine adjuvants: comparison of CpG ODN and Resiquimod (R-848). Vaccine, 2005. 23(45): p. 5263–70.
Wille-Reece, U., et al., Immunization with HIV-1 Gag protein conjugated to a TLR7/8 agonist results in the generation of HIV-1 Gag-specific Th1 and CD8+ T cell responses. J Immunol, 2005. 174(12): p. 7676–83.
Itoh, T. and E. Celis, Transcutaneous immunization with cytotoxic T-cell peptide epitopes provides effective antitumor immunity in mice. J Immunother, 2005. 28(5): p. 430–7.
Klinman, D.M., et al., Use of CpG oligodeoxynucleotides as immune adjuvants. Immunol Rev, 2004. 199: p. 201–16.
Speiser, D.E., et al., Rapid and strong human CD8+ T cell responses to vaccination with peptide, IFA, and CpG oligodeoxynucleotide 7909. J Clin Invest, 2005. 115(3): p. 739–46.
Kim, T.W., et al., Enhancing DNA vaccine potency by combining a strategy to prolong dendritic cell life with intracellular targeting strategies. J Immunol, 2003. 171(6): p. 2970–6.
Sudowe, S., et al., Transcriptional targeting of dendritic cells in gene gun-mediated DNA immunization favors the induction of type 1 immune responses. Mol Ther, 2003. 8(4): p. 567–75.
Garg, S., et al., Genetic tagging shows increased frequency and longevity of antigen-presenting, skin-derived dendritic cells in vivo. Nat Immunol, 2003. 4(9): p. 907–12.
MartIn-Fontecha, A., et al., Regulation of dendritic cell migration to the draining lymph node: impact on T lymphocyte traffic and priming. J Exp Med, 2003. 198(4): p. 615–21.
Belli, F., et al., Vaccination of metastatic melanoma patients with autologous tumor-derived heat shock protein gp96-peptide complexes: clinical and immunologic findings. J Clin Oncol, 2002. 20(20): p. 4169–80.
Wang, H.Y., et al., Induction of CD4(+) T cell-dependent antitumor immunity by TAT-mediated tumor antigen delivery into dendritic cells. J Clin Invest, 2002. 109(11): p. 1463–70.
Mohty, M., et al., All-trans retinoic acid skews monocyte differentiation into interleukin-12-secreting dendritic-like cells. Br J Haematol, 2003. 122(5): p. 829–36.
Adams, S., et al., PT-100, a small molecule dipeptidyl peptidase inhibitor, has potent antitumor effects and augments antibody-mediated cytotoxicity via a novel immune mechanism. Cancer Res, 2004. 64(15): p. 5471–80.
Nefedova, Y., et al., Hyperactivation of STAT3 is involved in abnormal differentiation of dendritic cells in cancer. J Immunol, 2004. 172(1): p. 464–74.
Song, X.T., et al., An alternative and effective HIV vaccination approach based on inhibition of antigen presentation attenuators in dendritic cells. PLoS Med, 2006. 3(1): p. e11.
Nair, S., et al., Synergy between tumor immunotherapy and antiangiogenic therapy. Blood, 2003. 102(3): p. 964–71.
Gabrilovich, D.I., et al., Antibodies to vascular endothelial growth factor enhance the efficacy of cancer immunotherapy by improving endogenous dendritic cell function. Clin Cancer Res, 1999. 5(10): p. 2963–70.
Rini, B.I., et al., Combination immunotherapy with prostatic acid phosphatase pulsed antigen-presenting cells (provenge) plus bevacizumab in patients with serologic progression of prostate cancer after definitive local therapy. Cancer, 2006. 107(1): p. 67–74.
Borg, C., et al., Novel mode of action of c-kit tyrosine kinase inhibitors leading to NK cell-dependent antitumor effects. J Clin Invest, 2004. 114(3): p. 379–88.
Ghiringhelli, F., et al., CD4+CD25+ regulatory T cells inhibit natural killer cell functions in a transforming growth factor-beta-dependent manner. J Exp Med, 2005. 202(8): p. 1075–85.
Hodi, F.S., et al., Biologic activity of cytotoxic T lymphocyte-associated antigen 4 antibody blockade in previously vaccinated metastatic melanoma and ovarian carcinoma patients. Proc Natl Acad Sci U S A, 2003. 100(8): p. 4712–7.
Phan, G.Q., et al., Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma. Proc Natl Acad Sci U S A, 2003. 100(14): p. 8372–7.
Attia, P., et al., Autoimmunity correlates with tumor regression in patients with metastatic melanoma treated with anti-cytotoxic T-lymphocyte antigen-4. J Clin Oncol, 2005. 23(25): p. 6043–53.
Beck, K.E., et al., Enterocolitis in patients with cancer after antibody blockade of cytotoxic T-lymphocyte-associated antigen 4. J Clin Oncol, 2006. 24(15): p. 2283–9.
Curiel, T.J., et al., Blockade of B7-H1 improves myeloid dendritic cell-mediated antitumor immunity. Nat Med, 2003. 9(5): p. 562–7.
Watanabe, N., et al., BTLA is a lymphocyte inhibitory receptor with similarities to CTLA-4 and PD-1. Nat Immunol, 2003. 4(7): p. 670–9.
Carreno, B.M. and M. Collins, BTLA: a new inhibitory receptor with a B7-like ligand. Trends Immunol, 2003. 24(10): p. 524–7.
Francois Bach, J., Regulatory T cells under scrutiny. Nat Rev Immunol, 2003. 3(3): p. 189–98.
Jonuleit, H. and E. Schmitt, The regulatory T cell family: distinct subsets and their interrelations. J Immunol, 2003. 171(12): p. 6323–7.
Woo, E.Y., et al., Regulatory CD4(+)CD25(+) T cells in tumors from patients with early-stage non-small cell lung cancer and late-stage ovarian cancer. Cancer Res, 2001. 61(12): p. 4766–72.
Wolf, A.M., et al., Increase of regulatory T cells in the peripheral blood of cancer patients. Clin Cancer Res, 2003. 9(2): p. 606–12.
Curiel, T.J., et al., Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat Med, 2004. 10(9): p. 942–9.
Oldenhove, G., et al., CD4+ CD25+ regulatory T cells control T helper cell type 1 responses to foreign antigens induced by mature dendritic cells in vivo. J Exp Med, 2003. 198(2): p. 259–66.
Dannull, J., et al., Enhancement of vaccine-mediated antitumor immunity in cancer patients after depletion of regulatory T cells. J Clin Invest, 2005. 115(12): p. 3623–33.
Asavaroengchai, W., Y. Kotera, and J.J. Mule, Tumor lysate-pulsed dendritic cells can elicit an effective antitumor immune response during early lymphoid recovery. Proc Natl Acad Sci U S A, 2002. 99(2): p. 931–6.
Rapoport, A.P., et al., Restoration of immunity in lymphopenic individuals with cancer by vaccination and adoptive T-cell transfer. Nat Med, 2005.
Dudley, M.E., et al., Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma. J Clin Oncol, 2005. 23(10): p. 2346–57.
Gattinoni, L., et al., Removal of homeostatic cytokine sinks by lymphodepletion enhances the efficacy of adoptively transferred tumor-specific CD8+ T cells. J Exp Med, 2005. 202(7): p. 907–12.
Morgan, R.A., et al., Cancer Regression in Patients After Transfer of Genetically Engineered Lymphocytes. Science, 2006.
Overwijk, W.W., et al., Tumor regression and autoimmunity after reversal of a functionally tolerant state of self-reactive CD8+ T cells. J Exp Med, 2003. 198(4): p. 569–80.
Friedman, E.J., Immune modulation by ionizing radiation and its implications for cancer immunotherapy. Curr Pharm Des, 2002. 8(19): p. 1765–80.
Chen, Z., et al., Combined radiation therapy and dendritic cell vaccine for treating solid tumors with liver micro-metastasis. J Gene Med, 2005. 7(4): p. 506–17.
Chi, K.H., et al., Combination of conformal radiotherapy and intratumoral injection of adoptive dendritic cell immunotherapy in refractory hepatoma. J Immunother, 2005. 28(2): p. 129–35.
Lake, R.A. and B.W. Robinson, Immunotherapy and chemotherapy–a practical partnership. Nat Rev Cancer, 2005. 5(5): p. 397–405.
Gabrilovich, D.I., et al., Production of vascular endothelial growth factor by human tumors inhibits the functional maturation of dendritic cells. Nat Med, 1996. 2(10): p. 1096–103.
Gabrilovich, D.I., et al., Decreased antigen presentation by dendritic cells in patients with breast cancer. Clin Cancer Res, 1997. 3(3): p. 483–90.
Furumoto, K., et al., Induction of potent antitumor immunity by in situ targeting of intratumoral DCs. J Clin Invest, 2004. 113(5): p. 774–83.
Sharma, S., et al., Cytokines and chemokines are expressed at different levels in small and large murine colon-26 tumors following intratumoral injections of CpG ODN. Neoplasia, 2004. 6(5): p. 523–8.
Carpentier, A.F., et al., Successful treatment of intracranial gliomas in rat by oligodeoxynucleotides containing CpG motifs. Clin Cancer Res, 2000. 6(6): p. 2469–73.
Meng, Y., et al., Successful combination of local CpG-ODN and radiotherapy in malignant glioma. Int J Cancer, 2005. 116(6): p. 992–7.